Compass Pathways’ Post

View organization page for Compass Pathways, graphic

32,637 followers

Today, COMPASS Pathways announced pricing of a private placement financing for up to $285 million with leading healthcare investors, with approximately $125 million in gross proceeds at closing and up to an additional approximately $160 million if the warrants are fully exercised with cash.     Kabir Nath, CEO of COMPASS Pathways said, “We are grateful for the support of this group of sophisticated healthcare investors for our work to bring potentially transformative treatment for mental health conditions to patients urgently in need of better options. We thank these investors for their confidence in our rigorous approach to building a strong base of evidence for the potential of COMP360 psilocybin treatment to help people with treatment-resistant depression, post-traumatic stress disorder and anorexia nervosa. These funds will allow us to advance our pivotal phase 3 program in TRD and achieve important milestones in the development of COMP360. We view this investment as a validation of the potential of psychedelic medicine and the importance of a rigorous and evidence-based approach.” https://lnkd.in/e-kmhRNA

Brom Rector, CFA

Investing in bio and healthcare

1y

what a great investor list! this brings a lot of legitimacy to psychedelics

Gloria Leong, MBA, CSM

Senior Program & Project Management Leader | Chief of Staff

1y

It's so inspiring to see we're making movements with psychedelic medicine! Can't wait to read the results!

Like
Reply
Doug Drysdale

CEO at CYBIN Inc. (NYSE:CYBN) | Healthcare Investor & Advisor | EY Entrepreneur of the Year | 2020 Inc. 5000 | TWTR @insidepharma

1y

Very good news

Joseph Abraham

Chief Business Officer - Xerago, Founder @ GTMHQ 🌐 | Mission: Help enterprise and mid-market B2B leaders build cost optimal predictable GTM & revenue engines

1y

Congrats team COMPASS Pathways on achieving this incredible milestone! 👏

Like
Reply
Amy Beckenstrom

Senior Digital Health Scientist

1y

Amazing news, excited!

Like
Reply
Angela Terhune Hargrove

Psychedelics, AI, Clinical Trials, CNS, RWE, Pharma, Biotech, CRO, Addiction, Oncology, DCT, Life Sciences, Ketamine

1y

Congratulations, COMPASS Pathways!

Like
Reply
Adam Geiger

CEO @ AlchemistOne. Addiction Recovery. Psychedelics. Tech.

1y

Congratulations COMPASS Pathways

Like
Reply
Altaf Kara

Managing Director, Fernhurst Lodge Limited

1y

Congratulations George and the team at Compass Pathways.

Like
Reply
Matthew Robinson

Life Science Industry Leader - Aon UK. Help organisations optimise their risk capital and human capital strategies

1y

Congratulations all

Like
Reply
Patroski Lawson, MSP/CSW

CEO at The KPM Group DC LLC | Join Me in Solving for Long Standing Healthcare Inequities

1y

Congrats Matthew Owens

See more comments

To view or add a comment, sign in

Explore topics